| Autor: |
Torres-Rufas M; Hospital Universitario de La Princesa, Calle Diego de León 62, 28006 Madrid, Spain., Vicente-Rabaneda EF; Rheumatology Department, Instituto de Investigación Sanitaria de La Princesa (IIS-Princesa), Hospital Universitario de La Princesa, Calle Diego de León 62, 28006 Madrid, Spain., Cardeñoso L; Microbiology Department, IIS-Princesa, Hospital Universitario de La Princesa, Calle Diego de León 62, 28006 Madrid, Spain., Gutierrez A; Microbiology Department, IIS-Princesa, Hospital Universitario de La Princesa, Calle Diego de León 62, 28006 Madrid, Spain., Bong DA; Instituto Poal de Reumatología, Carrer de Castanyer, 15, Sarrià-Sant Gervasi, 08022 Barcelona, Spain.; Bellvitge Campus, Universitat de Barcelona, Carrer de la Feixa Llarga, s/n, L'Hospitalet de Llobregat, 08907 Barcelona, Spain., Valero-Martínez C; Rheumatology Department, Instituto de Investigación Sanitaria de La Princesa (IIS-Princesa), Hospital Universitario de La Princesa, Calle Diego de León 62, 28006 Madrid, Spain., Serra López-Matencio JM; Hospital Pharmacy Department, Hospital Universitario de La Princesa, Calle Diego de León 62, 28006 Madrid, Spain., García-Vicuña R; Rheumatology Department, Instituto de Investigación Sanitaria de La Princesa (IIS-Princesa), Hospital Universitario de La Princesa, Calle Diego de León 62, 28006 Madrid, Spain., González-Gay MA; Rheumatology Department, IIS-Fundación Jiménez Díaz, Hospital Universitario Fundación Jiménez Díaz, Avenida de los Reyes Católicos, 2, Moncloa-Aravaca, 28040 Madrid, Spain.; Medicine and Psychiatry Department, University of Cantabria, 39008 Santander, Spain., González-Álvaro I; Rheumatology Department, Instituto de Investigación Sanitaria de La Princesa (IIS-Princesa), Hospital Universitario de La Princesa, Calle Diego de León 62, 28006 Madrid, Spain., Castañeda S; Rheumatology Department, Instituto de Investigación Sanitaria de La Princesa (IIS-Princesa), Hospital Universitario de La Princesa, Calle Diego de León 62, 28006 Madrid, Spain. |
| Abstrakt: |
Novel mechanisms of COVID-19 vaccines raised concern about their potential immunogenicity in patients with rheumatoid arthritis (RA) undergoing immunomodulatory treatments. We designed a retrospective single-center study to investigate their effectiveness and safety in this population, analyzing data from the first vaccination program (December 2020-October 2021). Inclusion criteria were availability of post-vaccination serology and a minimum subsequent follow-up of 6 months. Binding antibody units (BAU/mL) ≥ 7.1 defined an adequate serological response. Post-vaccine COVID-19 incidence and its timing since vaccination, adverse events (AEs), and RA flares were recorded. Adjusted logistic and linear multivariate regression analyses were carried out to identify factors associated with vaccine response. We included 118 patients (87.2% women, age 65.4 ± 11.6 years, evolution 12.0 ± 9.6 years), of whom 95.8% had a complete vaccination schedule. Adequate humoral immunogenicity was achieved in 88.1% of patients and was associated with previous COVID-19 and mRNA vaccines, whereas smoking, aCCP, age, and DMARDs exerted a negative impact. Post-vaccine COVID-19 occurred in 18.6% of patients, a median of 6.5 months after vaccination. Vaccine AE (19.5%) and RA flares (1.7%) were mostly mild and inversely associated with age. Our results suggest that COVID-19 vaccines induce adequate humoral immunogenicity, with an acceptable safety profile in RA patients. |
